Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Craig E. Gordon"'
Autor:
Abraham Cohen-Bucay, Silvia E. Ramirez-Andrade, Craig E. Gordon, Jean M. Francis, Vipul C. Chitalia
Publikováno v:
Kidney Medicine, Vol 2, Iss 6, Pp 771-786 (2020)
Reactivation of BK virus (BKV) remains a dreaded complication in immunosuppressed states. Conventionally, BKV is known as a cause for BKV-associated nephropathy and allograft dysfunction in kidney transplant recipients. However, emerging studies have
Externí odkaz:
https://doaj.org/article/fe9abad0340a4ecb8d972beaad88bec2
Autor:
Amandeep Godara, Daniel R. Migliozzi, Monika Pilichowska, Nitender Goyal, Cindy Varga, Craig E. Gordon
Publikováno v:
Kidney Medicine, Vol 2, Iss 5, Pp 652-656 (2020)
Transplant-associated thrombotic microangiopathy (TMA) in the post–organ transplantation setting occurs from a number of potential inciting factors, such as the use of calcineurin inhibitors, ischemic injury, infections, or antibody-mediated reject
Externí odkaz:
https://doaj.org/article/49353c1a2d1d4d13aa27ff63c0660a2c
Autor:
Priyamvada Singh, Hui Chen, Craig E. Gordon, Sandeep Ghai, J. Mark Sloan, Karen Quillen, Sara Moradi, Vipul Chitalia, Amitabh Gautam, Joel Henderson, Jean M. Francis
Publikováno v:
Kidney Medicine, Vol 1, Iss 3, Pp 139-143 (2019)
Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient o
Externí odkaz:
https://doaj.org/article/731970afc2ed48ad81f00a13e6aeffe2
Autor:
Michel Jadoul, Marina C. Berenguer, Wahid Doss, Fabrizio Fabrizi, Jacques Izopet, Vivekanand Jha, Nassim Kamar, Bertram L. Kasiske, Ching-Lung Lai, Jose´ M. Morales, Priti R. Patel, Stanislas Pol, Marcelo O. Silva, Ethan M. Balk, Craig E. Gordon, Amy Earley, Mengyang Di, Paul Martin
Publikováno v:
Počki, Vol 7, Iss 4, Pp 261-268 (2018)
No abstract
Externí odkaz:
https://doaj.org/article/3cdec82a2f454c6687b2921cafea2d3f
Publikováno v:
F1000Research, Vol 8 (2019)
Kidney transplantation (KT) is the most effective way to decrease the high morbidity and mortality of patients with end-stage renal disease. However, KT does not completely reverse the damage done by years of decreased kidney function and dialysis. F
Externí odkaz:
https://doaj.org/article/cfa152da939d4ee2881149e58d729126
Autor:
Craig E. Gordon, Ronald D. Perrone
Publikováno v:
Advances in Kidney Disease and Health. 30:207-208
Publikováno v:
Seminars in Nephrology. 42:14-28
Kidney transplantation remains the treatment of choice for patients with end-stage kidney disease. Significant progress has been made over the course of many years to improve both patient and graft outcomes after transplant. Modern immunosuppressive
Publikováno v:
American Journal of Kidney Diseases, (2023)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0f0ce97dcdd5df38d1ffb7ff84da4f
https://hdl.handle.net/2078.1/272294
https://hdl.handle.net/2078.1/272294
Autor:
Mengyang Di, Marina Berenguer, Michel Jadoul, Wahid Doss, Jacques Izopet, Fabrizio Fabrizi, Stanislas Pol, Amy Earley, Vivekanand Jha, Ethan M Balk, Craig E. Gordon, Priti R. Patel, Paul J. Martin, Ching-Lung Lai, Nassim Kamar, Bertram L. Kasiske, José M. Morales, Marcelo Silva
Publikováno v:
KIDNEYS. 7:261-268
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of t
Publikováno v:
Current Opinion in Nephrology & Hypertension. 30:493-500
Purpose of review The current review highlights advances in the use of direct-acting antiviral (DAA) agents in the treatment of hepatitis C virus (HCV) in chronic kidney disease (CKD) stages G4-5, end-stage renal disease, and kidney transplantation.